PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a leader...
Mental Health
Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
The results of pre-clinical in-vivo research studies suggested that Clearmind's drug candidate MEAI may be effective in the treatment of...
Neuronetics Announces Data Confirming Efficacy in Treating Anxious Depression with NeuroStar® Advanced Therapy for Mental Health
Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxietyMALVERN, Pa., Jan. 17, 2023 (GLOBE...
Canadian Centre for Agricultural Wellbeing welcomes TELUS Health as exclusive provider for mental health services
Services will help break down barriers to mental health support for farmers who may not have considered reaching out for...
VitalHub Announces Licensing Agreement With East Sussex Healthcare NHS Trust
TORONTO, Jan. 16, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the "Company" or "VitalHub") is pleased to announce a licensing agreement...
Mindbloom partners with This is Jane Project to offer affordable at-home ketamine therapy to trauma survivors
AUSTIN, Texas, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Mindbloom, the world’s largest provider of ketamine therapy, announced Monday the launch...
PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023
Company aims to commercialize wholly-owned KETARX™ (racemic ketamine) for mental health, neurological and pain disorders Company aims to seek FDA...
BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™
BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Heart to Heart CPR Raises Awareness of Ontario’s NEW Workplace Naloxone Requirements Effective June 1, 2023
TORONTO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- As of June 1, 2023, the Occupational Health and Safety Act (OHSA) will...
BrainsWay Resolves Neuronetics Litigation
BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Neuronetics Settles Litigation Against BrainsWay
MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on...
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a...
Nexalin Technology CEO Provides Letter to Shareholders
HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today provided the...
Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on...
Accolade Announces Participation in 25th Annual Needham Growth Conference
SEATTLE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the 25th...
VitalHub Announces Five Year Licensing Contract With Wirral University Teaching Hospital
TORONTO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) is pleased to announce a five-year licensing...
Nue Life Health Announces Launch of Nue Network Partnership Program For Medical Providers & Healthcare Systems
Program provides healthcare systems and medical providers access to Nue Life’s breakthrough mental health treatment programs and digital support toolsMIAMI,...
UpHealth Announces Third Quarter 2022 Financial Results
Third Quarter Revenues of $38.7 million; Gross Margin of 48%; Adjusted EBITDA of $(1.2) millionRevenues for the Nine-Month Period of...
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical Trial for Alcohol Use Disorder
Company engaged a leading clinical center in Israel and intends to conduct its first- in- human trial in the United...
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
- This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics, and analgesic activity of...